FINNENCE ▪ THE WIRE FILE
THE WIRE · № 70911
News■ Unclear/unknown
Saol Therapeutics Announces Completion of Enrollment in Pivotal Phase III BEACON Trial of SL1002 for the Treatment of Chronic Pain Related to Osteoarthritis of the Knee
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 11:30 UTC
LAST UPDATE2026-10-08 11:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Enrollment completion in a private Phase III pain trial is clinical progress without a listed-issuer link.
Private pain-therapy trial advances to data
CATALYST TO WATCH
Phase III BEACON topline results
MAIN RISK
Clinical failure risk remains unquantified
FULL DISPATCH
Company Also Announces End-of-Phase II Meeting with FDA to Discuss Planned Phase III Program for SL1002 for the treatment of Spasticity ROSWELL, Ga., DUBLIN and HAMILTON, Bermuda, Oct. 8, 2026 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform2026-10-08 11:30 UTC
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform2026-10-08 11:30 UTC
→CORRELATIONshares Healthcare
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk2026-10-08 11:38 UTC
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk2026-10-08 11:38 UTC
→CORRELATIONshares Healthcare
Expert consensus statement highlights promise of shared medical appointments for chronic disease care2026-10-08 11:43 UTC
Expert consensus statement highlights promise of shared medical appointments for chronic disease care2026-10-08 11:43 UTC
→CORRELATIONshares Healthcare
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies2026-10-08 11:45 UTC
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies2026-10-08 11:45 UTC
→CORRELATIONshares Healthcare
Cyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS)2026-10-08 12:10 UTC
Cyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS)2026-10-08 12:10 UTC
→CORRELATIONshares Healthcare
Vocca raises $20M after growing from 2,000 to 15,000 medical practitioners in a year2026-10-08 12:12 UTC
Vocca raises $20M after growing from 2,000 to 15,000 medical practitioners in a year2026-10-08 12:12 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.